Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies
Attempts to elicit antibodies with potent neutralizing activity against a broad range of human immunodeficiency virus (HIV) isolates have so far proven unsuccessful. Long-term delivery of monoclonal antibodies (mAbs) with such activity is a creative alternative that circumvents the need for an immun...
Main Authors: | Sebastian P Fuchs, Ronald C Desrosiers |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-01-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050116301954 |
Similar Items
-
Recombinant AAV Vectors for Enhanced Expression of Authentic IgG.
by: Sebastian P Fuchs, et al.
Published: (2016-01-01) -
High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes
by: Matthew R. Gardner, et al.
Published: (2022-03-01) -
Successful Transduction with AAV Vectors after Selective Depletion of Anti-AAV Antibodies by Immunoadsorption
by: Alejandro Orlowski, et al.
Published: (2020-03-01) -
OP 6.3 – 00150 Delivery and long-term expression of CCR5-blocking monoclonal antibody Leronlimab with AAV for ART-free remission from SHIV viremia
by: G. Webb, et al.
Published: (2022-12-01) -
Gene Transfer in Rodent Nervous Tissue Following Hindlimb Intramuscular Delivery of Recombinant Adeno-Associated Virus Serotypes AAV2/6, AAV2/8, and AAV2/9
by: Asad Jan, et al.
Published: (2019-11-01)